Josee Zijlstra
Overview
Explore the profile of Josee Zijlstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pfaehler E, Euba D, Rinscheid A, Hoekstra O, Zijlstra J, van Sluis J, et al.
EJNMMI Phys
. 2022 Aug;
9(1):53.
PMID: 35943622
Background: Machine learning studies require a large number of images often obtained on different PET scanners. When merging these images, the use of harmonized images following EARL-standards is essential. However,...
2.
Placa J, Diepstra A, Los T, Mendeville M, Seitz A, Lugtenburg P, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267654
Multiple gene expression profiles have been identified in diffuse large B-cell lymphoma (DLBCL). Besides the cell of origin (COO) classifier, no signatures have been reproduced in independent studies or evaluated...
3.
Schuster M, Zijlstra J, Casasnovas R, Vermaat J, Kalakonda N, Goy A, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jan;
22(7):483-494.
PMID: 35078739
Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral...
4.
Slot S, van de Donk N, Otten R, Boden B, Zijlstra J, Raijmakers P, et al.
Cancer Imaging
. 2021 Apr;
21(1):36.
PMID: 33879266
Background: Diagnostic and treatment response criteria for the JAK2/CALR/MPL mutation-related myeloproliferative neoplasms (MPNs) are largely based on bone marrow (BM) biopsy results. However, these biopsies have several limitations, such as...
5.
Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, et al.
Future Oncol
. 2021 Feb;
17(11):1295-1310.
PMID: 33528286
Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Functional Assessment of Cancer Therapy (FACT) -...
6.
Eeltink C, Lissenberg-Witte B, Incrocci L, Braamse A, Visser O, Zijlstra J, et al.
Sex Med
. 2020 Jun;
8(3):428-435.
PMID: 32507555
Introduction: Unambiguous data on sexual dysfunction after Hodgkin lymphoma (HL) treatment are scarce. Aims: To form a baseline in this area, we compared patient-reported sexual function in sexually active male...
7.
Pfaehler E, Burggraaff C, Kramer G, Zijlstra J, Hoekstra O, Jalving M, et al.
PLoS One
. 2020 Apr;
15(3):e0230901.
PMID: 32226030
Background: PET-based tumor delineation is an error prone and labor intensive part of image analysis. Especially for patients with advanced disease showing bulky tumor FDG load, segmentations are challenging. Reducing...
8.
Kaalep A, Burggraaff C, Pieplenbosch S, Verwer E, Sera T, Zijlstra J, et al.
EJNMMI Phys
. 2019 Dec;
6(1):28.
PMID: 31879795
Purpose: Recently, updated EARL specifications (EARL2) have been developed and announced. This study aims at investigating the impact of the EARL2 specifications on the quantitative reads of clinical PET-CT studies...
9.
Langendam M, Scholten R, Noel-Storr A, Thomas J, Marshall I, Wallace B, et al.
Diagn Progn Res
. 2019 May;
1:11.
PMID: 31095132
[This corrects the article DOI: 10.1186/s41512-016-0001-y.].
10.
Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, et al.
Haematologica
. 2018 Nov;
104(4):e151-e153.
PMID: 30381303
No abstract available.